{"6nj9hw8AAAAJ": [["Rosemarylin Or", 2020, "Molecular Classification of Diffuse Gliomas"], ["Sam Babak", 2020, "Molecular Classification of Diffuse Gliomas"], ["Navya Kalidindi", 2020, "Molecular Classification of Diffuse Gliomas"], ["Jeffrey Yachnin", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Filip De Vos", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Vivek Subbiah", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Jean-Yves Blay", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Gerald Prager", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Patrick Wen", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Tae Min Kim", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Sascha Dietrich", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Jacques De Greve", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Ilan Palanichamy", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Martin van den Bent", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Aislyn Boran", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Ralf-Dieter Hofheinz", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Anas Gazzah", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Carlos Gomez-Roca", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Jose Lopez-Martin", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Nikolas von Bubnoff", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Paul Burgess", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Angelica Fasolo", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Myra van Linde", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Mario Campone", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Daniel Cho", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Albert Lai", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Eduard Gasal", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["Alexander Stein", 2019, "ACTR-30. UPDATED EFFICACY AND SAFETY OF DABRAFENIB PLUS TRAMETINIB IN PATIENTS WITH RECURRENT/REFRACTORY BRAF V600E\u2013MUTATED HIGH-GRADE GLIOMA (HGG) AND LOW-GRADE GLIOMA (LGG)"], ["H Artee Luchman", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Mary MacNeil", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Craig Harlos", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Dongsheng Tu", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Martin Smoragiewicz", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Lesley Seymour", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Roger Tsang", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Joana Sederias", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Sarah Lapointe", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Samuel Weiss", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["John P Rossiter", 2019, "A phase I study of vistusertib (dual mTORC1/2 inhibitor) in patients with previously treated glioblastoma multiforme: a CCTG study"], ["Manmeet S Ahluwalia", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Wenya Linda Bi", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["E Antonio Chiocca", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Tracy T Batchelor", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Patrick Y Wen", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Lisa M Deangelis", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Mark R Gilbert", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["J Ricardo McFaline-Figueroa", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Howard Colman", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Susan M Chang", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["L Burt Nabors", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Janet Lo", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Linda M Liau", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Mary Jane Lim-Fat", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Evanthia Galanis", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Ugonma Chukwueke", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Timothy F Cloughesy", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Ingo K Mellinghoff", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Lakshmi Nayak", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["John F De Groot", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Andrew B Lassman", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Eudocia Quant Lee", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["David A Reardon", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["Minesh P Mehta", 2019, "When less is more: Dexamethasone dosing for brain tumors"], ["AS Micko", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["T Meinel", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JW Walsh", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["HJ Reulen", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["PH Pedersen", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Douglas Hardesty", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["CG Fisher", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["E Knosp", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["R Schouten", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["H Gittleman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["G O\u2019Donoghue", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Ahmed Mohyeldin", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["BW Scheithauer", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Ricardo J Komotar", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["A Lacroix", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RM Owens", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["H Ohgaki", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Mostafa Shahein", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["SN Kalkanis", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Russell R Lonser", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["PW Elwood", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["DN Louis", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["U Pichlmeier", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["MA Arriaga", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["ME Hegi", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["C Matthies", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JR Lister", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["S Giannotta", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JR Dusick", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["H Kano", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["E Lis", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Steven Giannotta", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["MS Greenberg", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RA Friedman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["A Khan", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["N Arredondo", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["QT Ostrom", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["ME Linskey", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["H Fortnum", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RL Carrau", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["SL Giannotta", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Gabriel Zada", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["EB Claus", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["D Simpson", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["R Stupp", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["DG Rubin", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RA Feelders", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["T Fukushima", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["P Moller", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["F Zanella", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["S Wolfsberger", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["EH Oldfield", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["F Esposito", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["E Myrseth", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["WF Regine", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Juan Manuel Revuelta", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["LK Nieman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["WK Cavenee", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Ricardo L Carrau", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["G Mehta", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JW House", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["MJ van den Bent", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["ME Molitch", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["J Wiemels", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["DA Chen", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Daniel M Prevedello", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JB Posner", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Daniel E Spratt", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["von Deimling", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["HR Winn", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["A Perry", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Simon S Buttrick", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["A W\u00f6hrer", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["D Baguley", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Alexandre Todeschini", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["J Bradley Elder", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RA Patchell", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["B Harris", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["P Liao", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["AL Versteeg", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["HD Jho", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["OD Wiestler", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["JC Flickinger", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["PA Tibbs", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Sheikh C Ali", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["M Lund-Johansen", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["I Laufer", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["M Wrensch", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["G Zada", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["WC Olivero", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["L Nieman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["LE Gaspar", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["D Kondziolka", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["P Cohan", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Jonathan H Sherman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Nicholas J Szerlip", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["IT Gavrilovic", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["H Budka", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["L Chin", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["DE Brackmann", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Ammar Shaikhouni", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["J Rennert", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["AL Asher", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["M Samii", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["P Yashar", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["RR Lonser", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["W Stummer", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["LD Lunsford", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["WP Mason", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["AC Diserens", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["A Doerfler", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["DW Andrews", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["David Dornbos III", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["TP Nikolopoulos", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["Roberto J Perez-Roman", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["CA Stratakis", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["T Gorlia", 2019, "Reliability of the spinal instability neoplastic score (SINS) among radiation oncologists: an assessment of instability secondary to spinal metastases"], ["U Metser", 2019, "18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or \u2026"], ["R Poon", 2019, "18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or \u2026"], ["W Mason", 2019, "18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or \u2026"], ["C Harlos", 2019, "18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or \u2026"], ["P MacCrostie", 2019, "18F-Fluorodeoxyglucose positron-emission tomography for the investigation of malignancy in patients with suspected paraneoplastic neurologic syndromes and negative or \u2026"], ["Wenjiang Zhang", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Kenneth D Aldape", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Gelareh Zadeh", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Farshad Nassiri", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Romina Nejad", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Hao-Wen Sim", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Eric X Chen", 2019, "Tissue 2-hydroxyglutarate as a biomarker for Isocitrate Dehydrogenase mutations in gliomas"], ["Michael A Vogelbaum", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Warren P Mason", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Mircea Tesileanu", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Johan M Kros", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Pim French", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Paul M Clement", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Martin J Van Den Bent", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Brigitta G Baumert", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Jean-Francois Baurain", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Alba Ariela Brandes", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Vassilis Golfinopoulos", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Pieter Wesseling", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Thierry Gorlia", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Michael Weller", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Helen Wheeler", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Sara Erridge", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Wolfgang Wick", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Marc Sanson", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Anna K Nowak", 2019, "Second interim and first molecular analysis of the EORTC randomized phase III intergroup CATNON trial on concurrent and adjuvant temozolomide in anaplastic glioma without 1p \u2026"], ["Nancy Levin", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Santosh Kesari", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Dawit Gebremichael Aregawi", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Patrick Roth", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Marie-Laure Casadebaig", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Benjamin Winograd", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Annick Desjardins", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Ileana Elias", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["David Eric Piccioni", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Daniela Annenelie Bota", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Roger Stupp", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Steven D Reich", 2019, "Full enrollment results from an extended phase I, multicenter, open label study of marizomib (MRZ) with temozolomide (TMZ) and radiotherapy (RT) in newly diagnosed glioblastoma \u2026"], ["Jaap C Reijneveld", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Emilie Le Rhun", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Maureen Vanlancker", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Frederic Dhermain", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Filip Yves Francine Leon De Vos", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Christopher J O'Callaghan", 2019, "EORTC 1709/CCTG CE. 8: A phase III trial of marizomib in combination with standard temozolomide-based radiochemotherapy versus standard temozolomide-based radiochemotherapy \u2026"], ["Nadine M Richard", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Alejandro Berlin", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Catherine Maurice", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["David B Shultz", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Kim Edelstein", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Barbara-Ann Millar", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Normand Laperriere", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Lori J Bernstein", 2019, "Cognitive rehabilitation for executive dysfunction in brain tumor patients: a pilot randomized controlled trial"], ["Margaret Wierman", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Santanu Sen", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Rebecca Loret De Mola", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Gidi Rechavi", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Alvaro Lassaletta", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Ted Laetsch", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Ayse Bahar Ercan", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Daniel Bowers", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Michal Oren", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Vanan Magimairajan", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Gavin Dunn", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Cynthia Hawkins", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Deborah Blumenthal", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Stefanie Zimmermann", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Melissa Edwards", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Sumita Roy", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Cindy Zhang", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Kami Schneider", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Patrick Tomboc", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Michael Taylor", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Nobuko Hijiya", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Gary Mason", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Ben George", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Annika Bronsema", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Enrico Opocher", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["David Ziegler", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Shlomi Constantini", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Carol Durno", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Charlotta Fr\u00f6jd", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Alyssa Reddy", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Duncan Stearns", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Kristina Cole", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Sumedha Sudhaman", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Elisabeth Koustenis", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Scott Lindhorst", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Tatiana Lipman", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Rina Dvir", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Melyssa Aronson", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Trevor Pugh", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Jacalyn Kelly", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["David Samuel", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Eric Bouffet", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Alexander Lossos", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Ailish Coblentz", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Kim Nichols", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Lauren Sambira", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Karen Gauvain", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Michal Zapotocky", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Maura Massimino", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Brittany Campbell", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Anne Bendel", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Daniel Morgenstern", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Mark Remke", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Michael Osborn", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Jiil Chung", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Sara Carroll", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Lindsey Hoffman", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Magnus Sabel", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Peter Dirks", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Val\u00e9rie Larouche", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Stefano Chiaravalli", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["David Sumerauer", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Adam Shlien", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Ira Winer", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["David Gass", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Oz Mordechai", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Gregory Thomas", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Uri Tabori", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Lee Yi Yen", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Jeffrey Knipstein", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["An Van Damme", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Stefan Bielack", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Sandra Luna-Fineman", 2019, "IMMU-20. IMMUNE AND TUMOR BIOMARKERS OF OUTCOME IN REPLICATION REPAIR DEFICIENT BRAIN TUMORS TREATED WITH IMMUNE CHECKPOINT INHIBITORS: UPDATES FROM THE INTERNATIONAL \u2026"], ["Claude Steriade", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Marvin Fritzler", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["P\u00e8ter K\u00f6ertvelyessy", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Harald Pr\u00fcss", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["John C Morris", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["David Tang-Wai", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Jack Ladenson", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Anne Fagan", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Elizabeth Herries", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Fatima Amtashar", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Gregory Day", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Robert Bucelli", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Julien Hebert", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Melanie Yarbrough", 2019, "Quantifying CSF Biomarkers of Neuronal Injury, Neuroinflammation and Synaptic Integrity in Antibody-Mediated Encephalitis (P2. 2-001)"], ["Vittorina Zagonel", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Josef Pichler", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Gaetano Finocchiaro", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Patrick Beauchesne", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Alba A Brandes", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["George Fountzilas", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Fran\u00e7ois Dubois", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Dana Michaela Cernea", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Oliver Chinot", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Frank Saran", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Antoine F Carpentier", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Rodica Anghel", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Martina Makrutzki", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Enrico Franceschi", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Francois Ghiringhelli", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Chiedzo Mpofu", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Miguel Gil-Gil", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Giuseppe Lombardi", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Hans Joerg Urban", 2019, "A Randomized phase II trial (TAMIGA) evaluating the efficacy and safety of continuous bevacizumab through multiple lines of treatment for recurrent glioblastoma"], ["Henry Chan", 2019, "Significance of treatment response when managing patients with primary central nervous system lymphoma"], ["Fabio Ynoe Moraes", 2019, "Significance of treatment response when managing patients with primary central nervous system lymphoma"], ["John Kuruvilla", 2019, "Significance of treatment response when managing patients with primary central nervous system lymphoma"], ["Anca Prica", 2019, "Significance of treatment response when managing patients with primary central nervous system lymphoma"], ["Michael Crump", 2019, "Significance of treatment response when managing patients with primary central nervous system lymphoma"], ["Kristina A Cole", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Theodore W Laetsch", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Valerie Larouche", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Ashraf Shamvil", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Ariane Mandel", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Gagan B Panigrahi", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Andrew Y Shuen", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Lisa Yu", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Nataliya Zhukova", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Bruce Crooks", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Helen Toledano", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Mark Bernstein", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Steve Gallinger", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Jagadeesh Ramdas", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Stella Lanni", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["William D Foulkes", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Naureen Mushtaq", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Kara Semotiuk", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["David Malkin", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Roula Farah", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Rebecca C Luiten", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Christopher E Pearson", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Michael Oren", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Daniel C Bowers", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Andrea Seeley", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Garth Nicholas", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Brittany B Campbell", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Kami Wolfe Schneider", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Yi Yen Lee", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Luis Alberto Pedroza", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Musa Alharbi", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Laura Palma", 2019, "Functional repair assay for the diagnosis of constitutional mismatch repair deficiency from non-neoplastic tissue"], ["Gregory Pond", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["Ilyse Lax", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["Felicity Backhouse", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["Kristin Campbell", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["David Shultz", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["Lori Bernstein", 2018, "RBTT-04. DOES EXERCISE IMPROVE PROGRESSION FREE SURVIVAL AND QUALITY OF LIFE IN PATIENTS WITH GLIOBLASTOMA? A TRIAL IN PROGRESS"], ["Lauren E Abrey", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Davis C Woodworth", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Roger Henriksson", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Robert J Harris", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Ararat Chakhoyan", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Ryo Nishikawa", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Whitney B Pope", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Josep Garcia", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Benjamin M Ellingson", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Olivier Chinot", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Arnav Mehta", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Kevin Leu", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["Catalina Raymond", 2018, "Post-chemoradiation volumetric response predicts survival in newly diagnosed glioblastoma treated with radiation, temozolomide, and bevacizumab or placebo"], ["David F Tang-Wai", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Melanie L Yarbrough", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Elizabeth M Herries", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Robert C Bucelli", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Marvin J Fritzler", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Jack H Ladenson", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Peter Koertvelyessy", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Gregory S Day", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Harald Pruess", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["Anne M Fagan", 2018, "Quantifying Biomarkers of Neuronal Injury, Neuroinflammation and Neurotransmission in Antibody-Mediated Encephalitis"], ["S Das", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["G Zadeh", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["H Soliman", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["J Brown", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["N Laperriere", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["G Nicholas", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["J Perry", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["LC Ang", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["D Macdonald", 2018, "Cancer Care Ontario Gliomas Guideline: An Endorsement of the 2017 European Association for Neuro-Oncology (EANO) Guideline on the Diagnosis and Treatment of Adult Astrocytic \u2026"], ["Magalie Hilton", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Martin JB Taphoorn", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Christina Theodore-Oklota", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Timothy Cloughesy", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Andrew Bottomley", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Olivier L Chinot", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["Arliene Ravelo", 2015, "Health-related quality of life in a randomized phase III study of bevacizumab, temozolomide, and radiotherapy in newly diagnosed glioblastoma"], ["D Curran", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["F Pignatti", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["L Douw", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["KL Ligon", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["H Kim", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["S Paris", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["DR Macdonald", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["EQ Lee", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Monika Hegi", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["JJ Heimans", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["S Zheng", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["JC Ghosh", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["DA Reardon", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["JC Buckner", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["MJ Taphoorn", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["M van den Bent", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["BJ Fisher", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["M Sanson", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["SL Pugh", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["C Hu", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["WK Alfred Yung", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["David Schiff", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["HY Song", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["G Cairncross", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["H Blair", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Kenneth Aldape", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["FW Boele", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["PY Wen", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["SS Amini", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["JC Reijneveld", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Riccardo Soffietti", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["W Wu", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["E Shaw", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["KV Ballman", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["MD Siegelin", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["NK Aaronson", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["RB Jenkins", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["BH Kang", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["J Plescia", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Y Marie", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Sean Lawler", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["M Wang", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["V Vaira", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["EG Shaw", 2015, "Health-related quality of life in stable, long-term survivors of low-grade glioma"], ["Cedric Revil", 2015, "Re-operation After Progression: Safety/Efficacy from AVAglio, a Phase III Study in Newly Diagnosed Glioblastoma"], ["Sunita Dhar", 2015, "Re-operation After Progression: Safety/Efficacy from AVAglio, a Phase III Study in Newly Diagnosed Glioblastoma"], ["Monika E Hegi", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Christine Marosi", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Sebastian Kurscheid", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["David Capper", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Gail Ryan", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Kh\u00ea Hoang-Xuan", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Jacoline E Bromberg", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Jeremy Rees", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Mohamed Ben Hassel", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Denis A Lacombe", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Andreas von Deimling", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Christian Hartmann", 2015, "Radiotherapy in relation to temozolomide: Subgroup analysis of molecular markers of the randomized phase III study by the EORTC/NCIC-CTG/TROG/MRC-CTU (EORTC 22033-26033) in \u2026"], ["Caroline Chung", 2015, "Rehabilitation of cognitive dysfunction in brain tumor patients."], ["Barbara Ann Millar", 2015, "Rehabilitation of cognitive dysfunction in brain tumor patients."], ["Butler Marcus", 2015, "Guillain-barre syndrome after treatment with dabrafenib for metastatic recurrent melaloma.(P4. 232)"], ["James Perry", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Tom Mikkelson", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["David Eisenstat", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Pamela New", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Surasak Phuphanich", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["David Reardon", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Lynn Taylor", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["BI 1200.36 Trial Group and the Canadian Brain Tumour Consortium", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Louis Nabors", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Yolanda Madarnas", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["James R Perry", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Julie Cong", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["David Mathieu", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Michael Madison", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Pierre Whitlock", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["William Shapiro", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Mary V MacNeil", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Constantinos Hadjipanayis", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Karen Fink", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Pierre Giglio", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["David D Eisenstat", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Agnieszka Cseh", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Jana Portnow", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Rose Lai", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Petr Kavan", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Hal Hirte", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Sven Wind", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Yali Fu", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Sajeel Chowdhary", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Isabelle Valli\u00e8res", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Anusha Bolonna", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Louis B Nabors", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Jacob Easaw", 2015, "Phase I/randomized phase II study of afatinib, an irreversible ErbB family blocker, with or without protracted temozolomide in adults with recurrent glioblastoma"], ["Donald A Berry", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Michael D Prados", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Xiaobu Ye", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Jason T Huse", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Abdul Tawab-Amiri", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Jann N Sarkaria", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Bhupinder Mann", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Lorenzo Trippa", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Brian P O'Neill", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Keith L Ligon", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Paul S Mischel", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["John F Degroot", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["James M Boyett", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Tom Mikkelsen", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Karla V Ballman", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"], ["Brian M Alexander", 2015, "Brain malignancy steering committee clinical trials planning workshop: report from the targeted therapies working group"]]}